Merck Vaccines Unit To Be Headed By U.S. Human Health President McGlynn
This article was originally published in The Pink Sheet Daily
Executive Summary
Margaret McGlynn will succeed Adel Mahmoud in overseeing four launches planned for 2005-2006, including HPV vaccine Gardasil.
You may also be interested in...
ProQuad Vaccine BLA Review Extended To September
FDA has extended its review of Merck's measles, mumps, rubella and varicella vaccine ProQuad by three months until Sept. 30
Merck CEO Clark Brings Managed Care Expertise To Post; Gilmartin Retires
Richard Clark's appointment signals the importance Merck is placing on managed care ahead of the January 2006 start of the Medicare drug benefit. Merck also is highlighting Clark's manufacturing expertise, but acknowledges he will rely on Merck Research Labs President Peter Kim for advice on R&D strategy.
Merck Plans Pharmaceutical-Style Launch For HPV Vaccine Gardasil
Gardasil's marketing model will be closer to a blockbuster pharmaceutical than to a traditional vaccine, CEO Gilmartin says. The company sees a parallel to the roll-out of Fosamax for osteoporosis.